IS5778A - Stökkbrigði af mennskri lifrarbólgu B veiru og notkun hennar - Google Patents

Stökkbrigði af mennskri lifrarbólgu B veiru og notkun hennar

Info

Publication number
IS5778A
IS5778A IS5778A IS5778A IS5778A IS 5778 A IS5778 A IS 5778A IS 5778 A IS5778 A IS 5778A IS 5778 A IS5778 A IS 5778A IS 5778 A IS5778 A IS 5778A
Authority
IS
Iceland
Prior art keywords
mutants
virus
human hepatitis
hepatitis
human
Prior art date
Application number
IS5778A
Other languages
English (en)
Inventor
Jin Oon Chong
Keow Lim Gek
Zhao Yi
Ning Chen Wei
Original Assignee
Government Of The Republic Of Singapore, Ministryof Health, College Of Medicine Building
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The Republic Of Singapore, Ministryof Health, College Of Medicine Building filed Critical Government Of The Republic Of Singapore, Ministryof Health, College Of Medicine Building
Publication of IS5778A publication Critical patent/IS5778A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IS5778A 1998-06-19 2000-12-19 Stökkbrigði af mennskri lifrarbólgu B veiru og notkun hennar IS5778A (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SG1998/000046 WO1999066048A1 (en) 1998-06-19 1998-06-19 A mutant human hepatitis b viral strain and uses thereof

Publications (1)

Publication Number Publication Date
IS5778A true IS5778A (is) 2000-12-19

Family

ID=20429862

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5778A IS5778A (is) 1998-06-19 2000-12-19 Stökkbrigði af mennskri lifrarbólgu B veiru og notkun hennar

Country Status (22)

Country Link
US (1) US6558675B1 (is)
EP (1) EP1098981A1 (is)
JP (1) JP2002518014A (is)
KR (1) KR100498118B1 (is)
CN (1) CN1322251A (is)
AR (1) AR020093A1 (is)
AU (1) AU756866B2 (is)
BG (1) BG105066A (is)
BR (1) BR9815913A (is)
CA (1) CA2330935C (is)
HU (1) HUP0103409A3 (is)
IL (1) IL140364A0 (is)
IS (1) IS5778A (is)
MX (1) MXPA00012720A (is)
MY (1) MY118955A (is)
NO (1) NO20006456L (is)
NZ (1) NZ508890A (is)
PL (1) PL192129B1 (is)
TR (1) TR200003777T2 (is)
UA (1) UA73476C2 (is)
WO (1) WO1999066048A1 (is)
YU (1) YU80600A (is)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200643171A (en) * 2005-06-07 2006-12-16 Temasek Life Sciences Lab Ltd Porcine circovirus type 2 vaccines
CN117843811A (zh) 2019-09-30 2024-04-09 吉利德科学公司 Hbv疫苗和治疗hbv的方法
CN113201051B (zh) * 2021-04-27 2022-08-02 复旦大学 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401987D0 (en) 1994-02-02 1994-03-30 Imperial College Modified nucleic acid
AU4353897A (en) 1996-09-18 1998-04-14 Board Of Regents, The University Of Texas System Viral defective interfering particles and uses thereof

Also Published As

Publication number Publication date
CA2330935C (en) 2005-05-10
EP1098981A1 (en) 2001-05-16
JP2002518014A (ja) 2002-06-25
PL345573A1 (en) 2001-12-17
WO1999066048A1 (en) 1999-12-23
CA2330935A1 (en) 1999-12-23
HUP0103409A3 (en) 2003-10-28
PL192129B1 (pl) 2006-09-29
IL140364A0 (en) 2002-02-10
KR20010106129A (ko) 2001-11-29
NO20006456D0 (no) 2000-12-18
MY118955A (en) 2005-02-28
MXPA00012720A (es) 2002-05-08
NZ508890A (en) 2004-04-30
UA73476C2 (en) 2005-08-15
TR200003777T2 (tr) 2001-06-21
AR020093A1 (es) 2002-04-10
BR9815913A (pt) 2001-12-26
HUP0103409A2 (hu) 2001-12-28
NO20006456L (no) 2001-02-16
BG105066A (en) 2001-09-28
KR100498118B1 (ko) 2005-07-01
CN1322251A (zh) 2001-11-14
AU7795198A (en) 2000-01-05
US6558675B1 (en) 2003-05-06
YU80600A (sh) 2005-06-10
AU756866B2 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
PT946323E (pt) Pos de niobio e condensadores eletroliticos de niobio
NO983965D0 (no) Polymer-organoleire-kompositter og deres fremstilling
PT773957E (pt) Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos
DK1087778T3 (da) Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
DE69831755D1 (de) Optoakustische kontrastmittel und anwendungsverfahren
DK1033996T3 (da) Forebyggelse og behandling af amyloidogen sygdom
DK0445255T3 (da) Behandling af tilstande og sygdom
NO983235D0 (no) Fikstur og protese innbefattende samme
DK108997A (da) Fremstilling og krystalformer af 2-methylthien-benzodiazepin
DK1041990T3 (da) Præparat til behandling af respiratoriske sygdomme og hudsygdomme med mindst en leukotrien-antagonist og mindst et antihistamin
NO972983D0 (no) Sulfonamider og deres anvendelse
DE69930647D1 (de) Struktur-analoga von amin-basen und nucleosiden
DK1216046T3 (da) Hidtil ukendt kombination af loteprednol og antihistaminer
FI980246A (fi) Menetelmä keittimen käyttämiseksi ja keitin
DK0961609T3 (da) Fremgangsmåde til forbedring af sundhedstilstanden af hår og hovedbund
DK0876573T3 (da) Keramisk tænder og fremgangsmåde til anvendelse af samme
IS5777A (is) Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
PT826679E (pt) Compostos de naftilo intermediarios composicoes e metodos de utilizacao
NO20013085D0 (no) Fosfororganiske forbindelser og deres anvendelse
IS2087B (is) Lyfjasamsetningar af tizoxaníði og nitazoxaníði
DE69934810D1 (de) Neues hepatitis c viruspeptid und seine verwendung
IS5778A (is) Stökkbrigði af mennskri lifrarbólgu B veiru og notkun hennar
DE60021118D1 (de) Perfluorocopolymere von tetrafluoroethylen und perfluoroalkylvinylether
EP1068362A4 (en) HEPATITIS C VIRUS NS5B COMPOSITIONS AND METHOD FOR THEIR USE
DK0905128T3 (da) Fremgangsmåder og mellemprodukter egnede til fremstilling af antifolater